|
1
|
Fung SK and Lok AS: Management of patients
with hepatitis B virus-induced cirrhosis. J Hepatol. 42(Suppl 1):
S54–S64. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Huang YH, Wu JC, Chen SC, Chen CH, Chiang
JH, Huo TI, Lee PC, Chang FY and Lee SD: Survival benefit of
transcatheter arterial chemoembolization in patients with
hepatocellular carcinoma larger than 10 cm in diameter. Aliment
Pharmacol Ther. 23:129–135. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Rampone B, Schiavone B, Martino A, Viviano
C and Confuorto G: Current management strategy of hepatocellular
carcinoma. World J Gastroenterol. 15:3210–3216. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ng KK and Poon RT: Current treatment
strategy for hepatocellular carcinoma. Saudi Med J. 28:1330–1338.
2007.PubMed/NCBI
|
|
5
|
Makower D, Rozenblit A, Kaufman H, Edelman
M, Lane ME, Zwiebel J, Haynes H and Wadler S: Phase II clinical
trial of intralesional administration of the oncolytic adenovirus
ONYX-015 in patients with hepatobiliary tumors with correlative p53
studies. Clin Cancer Res. 9:693–702. 2003.PubMed/NCBI
|
|
6
|
Reid T, Galanis E, Abbruzzese J, Sze D,
Wein LM, Andrews J, Randlev B, Heise C, Uprichard M, Hatfield M, et
al: Hepatic arterial infusion of a replication-selective oncolytic
adenovirus (dl1520): phase II viral, immunologic, and clinical
endpoints. Cancer Res. 62:6070–6079. 2002.PubMed/NCBI
|
|
7
|
Abdul-Ghani R, Ohana P, Matouk I, Ayesh S,
Ayesh B, Laster M, Bibi O, Giladi H, Molnar-Kimber K, Sughayer MA,
et al: Use of transcriptional regulatory sequences of telomerase
(hTER and hTERT) for selective killing of cancer cells. Mol Ther.
2:539–544. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Mizukoshi E, Nakamoto Y, Marukawa Y, Arai
K, Yamashita T, Tsuji H, Kuzushima K, Takiguchi M and Kaneko S:
Cytotoxic T cell responses to human telomerase reverse
transcriptase in patients with hepatocellular carcinoma.
Hepatology. 43:1284–1294. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zou W, Luo C, Zhang Z, Liu J, Gu J, Pei Z,
Qian C and Liu X: A novel oncolytic adenovirus targeting to
telomerase activity in tumor cells with potent. Oncogene.
23:457–464. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Huang JJ, Lin MC, Bai YX, Jing DD, Wong
BC, Han SW, Lin J, Xu B, Huang CF and Kung HF: Ectopic expression
of a COOH-terminal fragment of the human telomerase reverse
transcriptase leads to telomere dysfunction and reduction of growth
and tumorigenicity in HeLa cells. Cancer Res. 62:3226–3232.
2002.PubMed/NCBI
|
|
11
|
Shay JW, Zou Y, Hiyama E and Wright WE:
Telomerase and cancer. Hum Mol Genet. 10:677–685. 2001. View Article : Google Scholar
|
|
12
|
Huo LF, Tang JW, Huang JJ, Huang PT, Huang
CF, Kung HF and Lin MC: Cancer immunotherapy targeting the
telomerase reverse transcriptase. Cell Mol Immunol. 3:1–11.
2006.PubMed/NCBI
|
|
13
|
Ng SS, Gao Y, Chau DH, Li GH, Lai LH,
Huang PT, Huang CF, Huang JJ, Chen YC, Kung HF and Lin MC: A novel
glioblastoma cancer gene therapy using AAV-mediated long-term
expression of human TERT C-terminal polypeptide. Cancer Gene Ther.
14:561–572. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Gong HX, He L, Li XP, Wang YD, Li Y, Huang
JJ, Wang Z, Xie D, Kung HF and Peng Y: Effective antitumor immunity
against murine gliomas using dendritic cells transduced with
hTERTC27 recombinant adenovirus. Oncol Rep. 27:1163–1169.
2012.PubMed/NCBI
|
|
15
|
Yin D, Woodruff M, Zhang Y, Whaley S, Miao
J, Ferslew K, Zhao J and Stuart C: Morphine promotes Jurkat cell
apoptosis through pro-apoptotic FADD/P53 and anti-apoptotic
PI3K/Akt/NF-kappaB pathways. J Neuroimmunol. 174:101–107. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Cowell JK and Franks LM: A rapid method
for accurate DNA measurements in single cells in situ using a
simple microfluorimeter and Hoechst 33258 as a quantitative
fluorochrome. J Histochem Cytochem. 28:206–210. 1980. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Osada S, Ebihara I, Setoguchi Y, Takahashi
H, Tomino Y and Koide H: Gene therapy for renal anemia in mice with
ploycystic kidney using an adenovirus vector encoding the human
erythropoietin gene. Kidney Int. 55:1234–1240. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Mohr A, Lyons M, Deedigan L, Harte T, Shaw
G, Howard L, Barry F, O’Brien T and Zwacka R: Mesenchymal stem
cells expressing TRAIL lead to tumour growth inhibition in an
experimental lung cancer model. J Cell Mol Med. 12:2628–2643. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Reid T, Warren R and Kirn D: Intravascular
adenoviral agents in cancer patients: lessons from clinical trial.
Cancer Gene Ther. 9:979–986. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kim NW, Piatyszek MA, Prowse KR, Harley
CB, West MD, Ho PL, Coviello GM, Wright WE, Weinrich SL and Shay
JW: Specific association of human telomerase activity with immortal
cells and cancer. Science. 266:2011–2015. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Liao ZL, Luo G, Xie X, Tang XD, Bai JY,
Guo H and Yang SM: Diepitope multiple antigen peptide of hTERT
trigger stronger anti-tumor immune responses in vitro. Int
Immunopharmacol. 16:444–450. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Hashimoto Y, Tazawa H, Teraishi F, Kojima
T, Watanabe Y, Uno F, Yano S, Urata Y, Kagawa S and Fujiwara T: The
hTERT promoter enhances the antitumor activity of an oncolytic
adenovirus under a hypoxic microenvironment. PLoS One.
7:e392922012. View Article : Google Scholar
|
|
23
|
Iezzi G, Boni A, Degl’Innocenti E, Grioni
M, Bertilaccio MT and Bellone M: Type 2 cytotoxic T lymphocytes
modulate the activity of dendritic cells toward type 2 immune
responses. J Immunol. 177:2131–2137. 2006. View Article : Google Scholar
|
|
24
|
Knutson KL and Disis ML: Tumor
antigen-specific T helper cells in cancer immunity and
immunotherapy. Cancer Immunol Immunother. 54:721–728. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Pipkin ME, Sacks JA, Cruz-Guilloty F,
Lichtenheld MG, Bevan MJ and Rao A: Interleukin-2 and inflammation
induce distinct transcriptional programs that promote the
differentiation of effector cytolytic T cells. Immunity. 32:79–90.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Nishihori Y, Kato K, Tanaka M, Okamoto T,
Hagiwara S, Araki N, Kogawa K, Kuribayashi K, Nakamura K and Niitsu
Y: Interleukin-2 gene transfer potentiates the
alpha-galactosylceramide-stimulated antitumor effect by the
induction of TRAIL in NKT and NK cells in mouse models of
subcutaneous and metastatic carcinoma. Cancer Biol Ther.
8:1763–1770. 2009. View Article : Google Scholar
|
|
27
|
Koido S, Homma S, Hara E, et al: In vitro
generation of cytotoxic and regulatory T cells by fusions of human
dendritic cells and hepatocellular carcinoma cells. J Transl Med.
6:512008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Oh ST, Kim CH, Park MY, Won EH, Sohn HJ,
Cho HI, Kang WK, Hong YK and Kim TG: Dendritic cells transduced
with recombinant adenoviruses induce more efficient anti-tumor
immunity than dendritic cells pulsed with peptide. Vaccine.
24:2860–2868. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Chen L, Tang XD, Yu ST, Ai ZH, Fang DC,
Cai YG, Luo YH, Liang GP and Yang SM: Induction of anti-tumour
immunity by dendritic cells transduced with hTERT recombinant
adenovirus in mice. J Pathol. 217:685–692. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Darlington GJ, Bernhard HP, Miller RA and
Ruddle FH: Expression of liver phenotypes in cultured mouse
hepatoma cells. J Natl Cancer Inst. 64:809–819. 1980.PubMed/NCBI
|
|
31
|
Gao Y, Ng SS, Chau DH, Yao H, Yang C, Man
K, Huang PT, Huang C, Huang JJ, Kung HF and Lin MC: Development of
recombinant adeno-associated virus and adenovirus cocktail system
for efficient hTERTC27 polypeptide-mediated cancer gene therapy.
Cancer Gene Ther. 15:723–732. 2008. View Article : Google Scholar : PubMed/NCBI
|
